ALEC Alector Inc

Price (delayed)

$10.725

Market cap

$882.96M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.36

Enterprise value

$473.47M

Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. The Company is developing a broad portfolio of innate immune system ...

Highlights
ALEC's EPS has soared by 86% YoY and by 20% from the previous quarter
Alector's net income has surged by 86% YoY and by 21% QoQ
The equity has increased by 17% YoY but it has decreased by 11% QoQ

Key stats

What are the main financial stats of ALEC
Market
Shares outstanding
82.33M
Market cap
$882.96M
Enterprise value
$473.47M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.29
Price to sales (P/S)
3.87
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.08
Earnings
Revenue
$227.45M
EBIT
-$28.02M
EBITDA
-$19.45M
Free cash flow
$483.34M
Per share
EPS
-$0.36
Free cash flow per share
$5.89
Book value per share
$3.26
Revenue per share
$2.77
TBVPS
$11.63
Balance sheet
Total assets
$954.46M
Total liabilities
$686.92M
Debt
$46.61M
Equity
$267.54M
Working capital
$748.05M
Liquidity
Debt to equity
0.17
Current ratio
6.24
Quick ratio
6.18
Net debt/EBITDA
21.06
Margins
EBITDA margin
-8.5%
Gross margin
100%
Net margin
-12.7%
Operating margin
-12.7%
Efficiency
Return on assets
-3.8%
Return on equity
-10.6%
Return on invested capital
-8.7%
Return on capital employed
-3.5%
Return on sales
-12.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALEC stock price

How has the Alector stock price performed over time
Intraday
1.95%
1 week
25.73%
1 month
22.01%
1 year
-48.93%
YTD
-48.06%
QTD
-24.74%

Financial performance

How have Alector's revenue and profit performed over time
Revenue
$227.45M
Gross profit
$227.45M
Operating income
-$28.85M
Net income
-$28.78M
Gross margin
100%
Net margin
-12.7%
The net margin has soared by 99% YoY and by 27% from the previous quarter
ALEC's operating margin has surged by 99% year-on-year and by 29% since the previous quarter
Alector's net income has surged by 86% YoY and by 21% QoQ
ALEC's operating income has surged by 86% year-on-year and by 23% since the previous quarter

Growth

What is Alector's growth rate over time

Valuation

What is Alector stock price valuation
P/E
N/A
P/B
3.29
P/S
3.87
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.08
ALEC's EPS has soared by 86% YoY and by 20% from the previous quarter
ALEC's P/B is 47% below its last 4 quarters average of 6.1
The equity has increased by 17% YoY but it has decreased by 11% QoQ
The stock's price to sales (P/S) is 85% less than its last 4 quarters average of 25.0
The revenue has increased by 10% since the previous quarter

Efficiency

How efficient is Alector business performance
ALEC's ROS has soared by 99% YoY and by 30% from the previous quarter
Alector's ROA has soared by 90% YoY and by 34% from the previous quarter
The return on equity has surged by 85% year-on-year and by 24% since the previous quarter
The return on invested capital has surged by 83% year-on-year and by 28% since the previous quarter

Dividends

What is ALEC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALEC.

Financial health

How did Alector financials performed over time
ALEC's total assets is 39% greater than its total liabilities
ALEC's total assets has surged by 117% year-on-year and by 17% since the previous quarter
ALEC's total liabilities is up by 34% since the previous quarter
The debt is 83% less than the equity
The debt to equity is down by 23% year-on-year but it is up by 6% since the previous quarter
The equity has increased by 17% YoY but it has decreased by 11% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.